Tech Crunch

Cardiac Biomarkers Testing Market Size, Growth, Production, Trends and Forecast 2019-2026

Pressmeddelande   •   Jan 08, 2020 19:32 CET

The global ​cardiac biomarkers testing market size was estimated at $7.72 billion in 2018 and is expected to reach $18.19 billion by 2026, growing at a CAGR of 11.2% from 2019 to 2026. The report offers a detailed analysis of top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and wavering market trends.

Growing prevalence of cardiovascular diseases, technological advancements using cardio biomarkers combinations and increasing point of care (POC) testing have fueled the growth of the global cardiac biomarkers testing market. On the other hand, the complex process related to the course and several stringent government regulations hamper the growth to some extent. However, increase in the use of personalized medicine and rise in point of care testing using cardiac biomarkers are expected to create multiple opportunities in the market.

The report analyzes and forecasts the cardiac biomarkers testing market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

Get Free Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/29011

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global cardiac biomarkers testing market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the cardiac biomarkers testing market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of cardiac biomarkers testing market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

Key Players Insights:

The report provides a comprehensive analysis of the key players operating in the global cardiac biomarkers testing market. These players are Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, PerkinElmer Inc., Tosoh Corporation, Danaher Corporation, and Thermo Fisher Scientific.

The other players operating in the global cardiac biomarkers testing market include Randox Laboratories, Johnson and Johnson, Olympus Corporation, BG Medicines, ACS Biomarker B.V., and Cavadis Biomedical.

Get 20% Discount Here@ https://www.visionresearchreports.com/report/discount/29011

Segmentation:

By Type

  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others

By Application

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Point of Care Testing
  • Laboratory Testing

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global cardiac biomarkers testing capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
  • Focuses on the key cardiac biomarkers testing manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Buy This Premium Research Report@ https://www.visionresearchreports.com/report/cart/29011

Table of Content

Section 1: Introduction

1.1. Market Report description
1.2. Market Key benefits for stakeholders
1.3. Key market segments
1.4. market Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Section 2: Market EXECUTIVE SUMMARY

2.1. Key findings

2.1.1. Top impacting factors
2.1.2. Top investment pockets

2.2. CXO perspective

Section 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers

3.3.1. Early diagnosis
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output

3.4. Key trends impacting the Cardiac biomarker testing market

3.4.1. Development of high sensitive biomarkers for risk stratification
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics

3.5. Parent Market Overview
3.6. Key Forces Shaping Cardiac biomarker testing market

3.6.1. High bargaining power of suppliers
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry

3.7. Value chain analysis
3.8. Pricing Analysis

3.8.1. Pricing Analysis, By Region, 2018 & 2025

3.9. Market evolution/Industry roadmap
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis

3.12.1. By Region (2016-2018)
3.12.2. By Applicant

3.13. Market share analysis
3.14. Case Studies

3.14.1. Case Study

3.15. Market dynamics

3.15.1. Drivers

3.15.1.1. Increasing prevalence of cardiovascular diseases
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing

3.15.2. Restraints

3.15.2.1. Government Regulation
3.15.2.2. Conformation in result
3.15.2.3. Complex process

3.15.3. Opportunities

3.15.3.1. Personalized medicine
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers

Section 4: CARDIAC BIOMARKER TESTING MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Creatine kinase (CK-MB)

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country

4.3. Troponins

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Myoglobin

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

4.5. Natriuretic peptides (BNP and NT-proBNP)

4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

4.6. Ischemia modified albumin

4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country

4.7. Others

4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country

Section 5: CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Myocardial infarction

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Congestive heart failure

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Acute coronary syndrome

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Atherosclerosis

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Other applications

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

Section 6: CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING

6.1. Overview

6.1.1. Market size and forecast

6.2. Point of care testing

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Laboratory testing

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

Section 7: CARDIAC BIOMARKER TESTING MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by type
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by location of testing
7.2.5. North America market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. U.S. market size and forecast, by type
7.2.5.1.2. U.S. market size and forecast, by application
7.2.5.1.3. U.S. market size and forecast, by location of testing

7.2.5.2. Canada

7.2.5.2.1. Canada market size and forecast, by type
7.2.5.2.2. Canada market size and forecast, by application
7.2.5.2.3. Canada market size and forecast, by location of testing

7.2.5.3. Mexico

7.2.5.3.1. Mexico market size and forecast, by type
7.2.5.3.2. Mexico market size and forecast, by application
7.2.5.3.3. Mexico market size and forecast, by location of testing

7.3. Europe

7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by type
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by location of testing
7.3.5. Europe market size and forecast, by country

7.3.5.1. UK

7.3.5.1.1. UK market size and forecast, by type
7.3.5.1.2. UK market size and forecast, by application
7.3.5.1.3. UK market size and forecast, by location of testing

7.3.5.2. France

7.3.5.2.1. France market size and forecast, by type
7.3.5.2.2. France market size and forecast, by application
7.3.5.2.3. France market size and forecast, by location of testing

7.3.5.3. Germany

7.3.5.3.1. Germany market size and forecast, by type
7.3.5.3.2. Germany market size and forecast, by application
7.3.5.3.3. Germany market size and forecast, by location of testing

7.3.5.4. Rest of Europe

7.3.5.4.1. Rest of Europe market size and forecast, by type
7.3.5.4.2. Rest of Europe market size and forecast, by application
7.3.5.4.3. Rest of Europe market size and forecast, by location of testing

7.4. Asia-Pacific

7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by type
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by location of testing
7.4.5. Asia-Pacific market size and forecast, by country

7.4.5.1. China

7.4.5.1.1. China market size and forecast, by type
7.4.5.1.2. China market size and forecast, by application
7.4.5.1.3. China market size and forecast, by location of testing

7.4.5.2. India

7.4.5.2.1. India market size and forecast, by type
7.4.5.2.2. India market size and forecast, by application
7.4.5.2.3. India market size and forecast, by location of testing

7.4.5.3. Australia

7.4.5.3.1. Australia market size and forecast, by type
7.4.5.3.2. Australia market size and forecast, by application
7.4.5.3.3. Australia market size and forecast, by location of testing

7.4.5.4. Japan

7.4.5.4.1. Japan market size and forecast, by type
7.4.5.4.2. Japan market size and forecast, by application
7.4.5.4.3. Japan market size and forecast, by location of testing

7.4.5.5. Rest of Asia-Pacific

7.4.5.5.1. Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2. Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3. Rest of Asia-Pacific market size and forecast, by location of testing

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by type
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by location of testing
7.5.5. LAMEA market size and forecast, by country

7.5.5.1. Latin America

7.5.5.1.1. Latin America market size and forecast, by type
7.5.5.1.2. Latin America market size and forecast, by application
7.5.5.1.3. Latin America market size and forecast, by location of testing

7.5.5.2. Middle East

7.5.5.2.1. Middle East market size and forecast, by type
7.5.5.2.2. Middle East market size and forecast, by application
7.5.5.2.3. Middle East market size and forecast, by location of testing

7.5.5.3. Africa

7.5.5.3.1. Africa market size and forecast, by type
7.5.5.3.2. Africa market size and forecast, by application
7.5.5.3.3. Africa market size and forecast, by location of testing

Section 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Becton, Dickinson and Company

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. BioMerieux

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance

8.4. Bio-Rad Laboratories, Inc.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance

8.5. Danaher Corporation

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance

8.6. F. HOFFMANN-LA ROCHE LTD.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance

8.7. Siemens AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance

8.8. Thermo Fisher Scientific, Inc.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance

8.9. PerkinElmer Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance

8.10. Tosoh Corporation

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance

Buy This Premium Research Report@ https://www.visionresearchreports.com/report/cart/29011

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.